Skip to main content
< Back to news
Gerard Caelles, chief business officer, and Miquel Vila-Perelló, co-founder and CEO of the company (Photo: SpliceBio).

SpliceBio receives Series A of the Year Award at the European Lifestars Awards

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies has received the ‘Series A Finance Raise of the Year’ at the European Lifestars Awards -organised by LSX (Life Science eXecutive partnering community)- in recognition of the €50M round closed in February, the largest series A raised by a biotech company in Spain. The company, based in the Barcelona Science Park, has been the winner from among a selection of 10 nominated companies from 7 European countries.

The awards ceremony was held on 14 November in London in a ceremony attended by more than 130 finalists from 18 countries competing in 18 categories.

SpliceBio has received the award in recognition of the €50M Series A round raised last February, the largest Series A ever raised by a biotech company in Spain. The round was led by Ysios Capital and UCB Ventures (Belgium), who were joined by an important syndicate of leading international biotech investors, including New Enterprise Associates (USA), Gilde HealthCare (Netherlands), Novartis (Switzerland) and Asabys Partners. Ysios has already led the company’s first round in 2020.

“We are very proud to receive this recognition for the financing round that SpliceBio closed last February. The jury considered not only the volume of funds raised, but also the quality of the investment syndicate, as well as the company’s innovative capacity”, comments Miquel Vila i Perelló, CEO of SpliceBio.

“We are particularly excited about this achievement because of the recognition it brings to our role as leaders in the round and in setting up an international syndicate, with leading investors in European and US biotech, which has never been seen in Spain in a company at such an early stage. We are very proud to have accompanied SpliceBio since it started in 2020, also leading a seed round to take the company to the next level,” says Joël Jean-Mairet, managing partner of Ysios Capital.

“SpliceBio stands out both for the quality of its management team and its technology. At Asabys we have believed in the company’s technological concept since the beginning and are proud to have the support of an international syndicate of investors to help the company in its mission to bring new therapeutic options to patients. The evolution of SpliceBio since our initial investment has made it natural to raise such a significant new round of funding and reaffirms our confidence in the Spanish entrepreneurial ecosystem”, concluded Sylvain Sachot, principal at Asabys Partners.

» Related news [+]